![Charlotte Keywood](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Charlotte Keywood
Keine laufenden Positionen mehr
Karriereverlauf von Charlotte Keywood
Ehemalige bekannte Positionen von Charlotte Keywood
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Axovan AG
![]() Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 | 01.01.2003 |
VERNALIS | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2001 | 01.01.2001 |
ADDEX THERAPEUTICS LTD | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2004 | - |
Statistik
International
Schweiz | 3 |
Vereinigtes Königreich | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Sektoral
Health Technology | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ADDEX THERAPEUTICS LTD | Health Technology |
Private Unternehmen | 2 |
---|---|
Axovan AG
![]() Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Commercial Services |
Ligand UK Ltd.
![]() Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Charlotte Keywood
- Erfahrung